Loading
Voyager Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by NEUROCRINE BIOSCIENCES INC, was filed 24 Feb 2023.
Voyager Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Voyager Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The last twelve months, up to 22 October 2026, brought 17 filings signed by 6 insiders.
There is no open-market purchase to report; the filings show 11 sales worth €253k by 4 insiders. The largest single trade was a sale of €46k by Sandrock Alfred, published on 26 February 2026.
For context, the typical company on the same exchange (median of 3,171 companies) published 24 filings over the same period, against 17 filings here. Looking back to 2016, when coverage begins, insiders filed 8 purchases and 116 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 40.4 m USD and net income at -119.7 m USD.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
194
Thresholds
n/a
Buy Volume
€84M
8 ops. · all time
Sell Volume
€23M
116 ops. · all time
Who traded when
BuySaleAlfred Sandrock7 sales
Robin Swartz7 sales
Todd Alfred Carter6 sales
Nathan D. Jorgensen2 sales
Toby Ferguson2 sales
Sandell Jacquelyn Fahey1 sale
Since the insiders bought
- +20.7%Entry US$7.16 · Close at T+365 US$8.64
- +105.2%Entry US$5.76 · Close at T+365 US$11.82
- -12.1%Entry US$19.55 · Close at T+365 US$17.19
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Voyager Therapeutics, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$14.89.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.06
Analyst consensus
9 analystsStrong buy
US$8.00Target US$14.89(+625%)US$25.00
Income statement
RevenueUS$40.4M
EBITDA-US$127.8M-317% margin
Net income-US$119.7M-296.5% margin
Valuation
PER (forward)-1.6x
P/Book0.8x
Beta1.28
Balance sheet & cash
Market capUS$126.6M
Total debtUS$36.5M
Free Cash Flow-US$135.1M
Debt / Equity21%
Profitability & ownership
ROE-54.1%
ROA-27.3%
% insiders14.8%
% institutions57.9%
Last declaration on 3 April 2026
Declarations194 total
11,511 shares@ US$3.876.8% of flowCommon StockSEC:0001104659-26-039691:0
50,000 shares0Common StockSEC:0001104659-26-039689:0
6,458 shares@ US$3.775.0% of flowCommon StockSEC:0001104659-26-020183:0
14,197 shares@ US$3.798.1% of flowCommon StockSEC:0001104659-26-020181:0
4,668 shares@ US$3.7732.3% of flowCommon StockSEC:0001104659-26-020179:0
4,174 shares@ US$3.766.6% of flowCommon StockSEC:0001104659-26-020176:0
3,882 shares@ US$3.442.8% of flowCommon StockSEC:0001104659-26-018131:0
3,301 shares@ US$3.444.8% of flowCommon StockSEC:0001104659-26-018130:0
11,732 shares@ US$3.416.0% of flowCommon StockSEC:0001104659-26-018126:0
3,525 shares@ US$3.855.7% of flowCommon StockSEC:0001104659-26-013408:0
4,569 shares@ US$3.853.6% of flowCommon StockSEC:0001104659-26-013416:0
12,192 shares@ US$3.786.9% of flowCommon StockSEC:0001104659-26-013414:0
45,000 shares0Common StockSEC:0001104659-26-012679:0
33,000 shares0Common StockSEC:0001104659-26-012677:0
45,000 shares0Common StockSEC:0001104659-26-012675:0
86,250 shares0Common StockSEC:0001104659-26-012672:0
32,250 shares0Common StockSEC:0001104659-26-012669:0
7,666 shares@ US$4.7867.7% of flowCommon StockSEC:0001104659-25-097522:0
19,000 shares@ US$3.7365.7% of flowCommon StockSEC:0001104659-25-080825:0
10,885 shares@ US$3.436.1% of flowCommon StockSEC:0001104659-25-032202:0
10,086 shares@ US$3.4334.3% of flowCommon StockSEC:0001104659-25-032208:0
46,000 shares0Common StockSEC:0001104659-25-016522:1
71,250 shares0Common StockSEC:0001104659-25-016516:1
145,000 shares0Common StockSEC:0001104659-25-016520:1
3,305 shares@ US$4.266.7% of flowCommon StockSEC:0001104659-25-016522:0
25 of 194 declarations
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. is a U.S.-listed biotechnology company traded on the Nasdaq Global Select Market under the ticker VYGR, and based in the United States. Its corporate headquarters are in Lexington, Massachusetts, in the greater Boston life sciences cluster. The company was launched in 2014 with support from Third Rock Ventures and was originally built around gene therapy programs for central nervous system disorders. Over time, Voyager has expanded into a broader neuroscience-focused platform aimed at leveraging human genetics to alter the course of neurological disease. ([voyagertherapeutics.com](https://www.voyagertherapeutics.com/?utm_source=openai))
Voyager’s strategic identity is highly focused: it seeks to use genetic medicine to address severe, often chronic neurological diseases with major unmet medical need. That focus differentiates it from larger diversified pharma groups and also from many gene therapy peers, because Voyager concentrates its scientific, clinical, and capital resources on neurology and on delivery technologies designed to reach the brain across the blood-brain barrier. The company combines wholly owned programs with select collaborations, helping it share development risk while retaining meaningful upside in key assets. ([voyagertherapeutics.com](https://www.voyagertherapeutics.com/?utm_source=openai))
Read moreShow less
On the business-line side, Voyager’s pipeline includes gene therapy and gene-silencing assets in Alzheimer’s disease, including tau-targeting programs, as well as programs in Parkinson’s disease, Friedreich’s ataxia, and GBA1-related diseases. In 2025, the company added a fourth wholly owned Alzheimer’s program centered on APOE, strengthening its Alzheimer’s franchise. Voyager is also developing Voyager NeuroShuttle™, a non-viral delivery platform designed for brain delivery, which highlights the company’s effort to broaden its modality mix beyond traditional viral vectors. ([voyagertherapeutics.com](https://www.voyagertherapeutics.com/pipeline-overview/?utm_source=openai))
From a competitive standpoint, Voyager remains a research- and development-driven biotech, meaning equity value is primarily tied to clinical data, regulatory milestones, partnering activity, and the ability to translate platform science into human proof of concept. Its core advantage is deep specialization in neurological disease, a segment that is scientifically challenging but potentially very large. Geographically, Voyager’s footprint is concentrated in the United States, with headquarters and operating activities centered in the Boston/Lexington, Massachusetts area. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1640266/000155837025002703/vygr-20241231x10k.htm?utm_source=openai))
Recent catalysts have been important. In 2025 and early 2026, Voyager highlighted progress across its tau assets in Alzheimer’s disease, planned clinical entry for several I.V.-delivered neuro gene therapies, and advancement of its NeuroShuttle platform. Management also stated that its cash runway extends into 2028, an important consideration for biotech investors assessing dilution risk and funding durability. For francophone investors, VYGR is therefore a U.S.-market Nasdaq biotechnology name with a pure-play neuroscience angle, where the investment case is driven by pipeline execution rather than current product sales. ([ir.voyagertherapeutics.com](https://ir.voyagertherapeutics.com/news-releases/news-release-details/voyager-reports-fourth-quarter-and-full-year-2025-financial-and?utm_source=openai))
